What question did this study set out to answer?

To characterize the clinical spectrum and identify predictors of mortality in patients presenting with an amyloid-negative, tau-positive neurodegenerative biomarker profile.

August 14, 2026Journal of Alzheimer s Disease

Prognostic significance of cerebrospinal fluid tau biomarkers in amyloid-negative A−T + N + neurodegeneration: A retrospective cohort study

View Full Paper

Ask AI

Bookmark

Authors

AGAslı Aksoy GündoğduTekirdağ Namık Kemal University BSBedia SamancıIstanbul University MAMerve AlaylıoğluIstanbul University-Cerrahpaşa

Discussion

Member takes

Implication

Retrospective cohort study reveals elevated cerebrospinal fluid total tau predicts mortality in amyloid-negative neurodegeneration, indicating distinct prognostic profiles.

Key Points

To characterize the clinical spectrum and identify predictors of mortality in patients presenting with an amyloid-negative, tau-positive neurodegenerative biomarker profile.
Retrospective cohort study of N=130 patients with normal CSF Aβ42 but elevated pTau and tTau, identified from 1,280 individuals screened at a tertiary neurology center.
Evaluated overall survival and mortality predictors using Kaplan–Meier survival analysis and multivariable Cox proportional hazards regression models.
The cohort exhibited diverse clinical diagnoses, primarily mild cognitive impairment (30%) and frontotemporal dementia (30%), with survival differing significantly across clinical groups (log-rank p = 0.037) and non-survivors more frequently male (88.9% vs. 45.6%, p < 0.001).
Higher CSF tTau levels were significantly associated with mortality in the joint Cox model (HR 1.003, 95% CI 1.001–1.006, p = 0.006) and correlated with faster clinical progression (r = 0.22, p = 0.011).

Cite This Study

Gündoğdu et al. (2026) studied this question.

synapsesocial.com/papers/6a7ec754b70b84ec8b913a24 https://doi.org/10.1177/13872877261476236

View Full Paper

Ask AI

Bookmark

August 14, 2026Journal of Alzheimer s Disease

Prognostic significance of cerebrospinal fluid tau biomarkers in amyloid-negative A−T + N + neurodegeneration: A retrospective cohort study

View Full Paper

Ask AI

Bookmark

Authors

AGAslı Aksoy GündoğduTekirdağ Namık Kemal University BSBedia SamancıIstanbul University MAMerve AlaylıoğluIstanbul University-Cerrahpaşa

Discussion

Member takes

Implication

Retrospective cohort study reveals elevated cerebrospinal fluid total tau predicts mortality in amyloid-negative neurodegeneration, indicating distinct prognostic profiles.

Key Points

To characterize the clinical spectrum and identify predictors of mortality in patients presenting with an amyloid-negative, tau-positive neurodegenerative biomarker profile.
Retrospective cohort study of N=130 patients with normal CSF Aβ42 but elevated pTau and tTau, identified from 1,280 individuals screened at a tertiary neurology center.
Evaluated overall survival and mortality predictors using Kaplan–Meier survival analysis and multivariable Cox proportional hazards regression models.
The cohort exhibited diverse clinical diagnoses, primarily mild cognitive impairment (30%) and frontotemporal dementia (30%), with survival differing significantly across clinical groups (log-rank p = 0.037) and non-survivors more frequently male (88.9% vs. 45.6%, p < 0.001).
Higher CSF tTau levels were significantly associated with mortality in the joint Cox model (HR 1.003, 95% CI 1.001–1.006, p = 0.006) and correlated with faster clinical progression (r = 0.22, p = 0.011).

Cite This Study

Gündoğdu et al. (2026) studied this question.

synapsesocial.com/papers/6a7ec754b70b84ec8b913a24 https://doi.org/10.1177/13872877261476236

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark